Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Kura Oncology, Inc.
Taiho Oncology, Inc.
Kura Oncology, Inc.
Celgene
Servier
Incyte Corporation
Molecular Partners AG
Bristol-Myers Squibb
Celgene
Novartis
Pfizer
Celgene
Incyte Corporation
Maxinovel Pty., Ltd.
Celgene
Calithera Biosciences, Inc